Celltrion’s Truxima, a copy of Roche`s blockbuster blood cancer medicine, will be launched in Colombia through local distributorship. The South Korea-based biopharmaceutical firm also revealed a plan to set up a local operation to penetrate the Latin American market.
Celltrion announced on Wednesday its global distributor Celltrion Healthcare signed a contract with multinational drugmaker Mundipharma to distribute Truxima in Colombia. Mundipharma has maintained its partnership with Celltrion in major European countries to market Truxima and another biosimilar Remsima.
Celltrion shares ended Wednesday 1.15 percent higher at 307,500 won ($344.27) on the main Kospi bourse.
The duo aims to launch Truxima in the first half of this year in Colombia. Separately, Celltrion plans to establish a local affiliate in the country by the end of June.
“We will prepare to launch Truxima also in the Dominican Republic, Guatemala, Nicaragua and Costa Rica in the first half of the year with an aim of expanding our market share in Latin America. By the end of this year, we will gradually expand sales to Ecuador and Peru,” said a Celltrion Healthcare official.
By Shin Chan-ok and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]